Ambrx

Next generation antibody drug conjugates using engineered precision biologics

Ambrx advanced protein biosynthesis, enabling the company to genetically engineer proteins with new amino acid building blocks beyond the existing 20 natural amino acids, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties.

Ambrx was acquired by Fosun Pharma in 2015.